| THURSDAY, MARCH 26, 2026 | ||
| 11:45-12:45 11:45-12:10 12:10-12:35 12:35-12:45 | Sanofi Industry Sponsored Symposium | HALL A Rethinking Multiple Sclerosis: Detecting and Disrupting Disability Accumulation Piecing Together the Early Signs of Disability Accumulation Prof. Celia Oreja-Guevara, Spain The Immune Network in MS: Pathways to Future Clinical Innovation Prof. Patrick Vermersch, France Q&A All Faculty |  |
| 13:00-13:50 13:00-13:20 13:20-13:40 13:40-13:50 | Meet the Expert Session sponsored by Britannia | HALL C Should subcutaneous therapy always be used before Intrajejunal therapy? Agree: Subcutaneous delivery is a clear choice in treating Parkinson’s Prof. Jaroslaw Slawek, Poland Disagree: Intrajejunal therapy should be considered alongside subcutaneous therapy Prof. Michal Minar, Slovakia Q&A All Faculty |  |
| 13:00-13:50 13:00-13:03 13:03-13:18 13:18-13:38 13:38-13:48 | Meet the Expert Session sponsored by Lilly | MTE HALL Advancing Alzheimer’s Care: From Biomarker-Based Diagnosis to Real-World Experience with Donanemab Welcome & Introduction Moderator: Prof. Konrad Rejdak, Poland Diagnostic Advances in Alzheimer’s Disease Speaker: Prof. Joanna Siuda, Poland First Clinical Experiences with Donanemab Speaker: Dr. Noa Bregman, Israel Panel Discussion and Q&A Moderator: Prof. Konrad Rejdak, Poland |  |
| FRIDAY, MARCH 27, 2026 | ||
| 11:10-12:10 11:10-11:15 11:15-11:35 11:35-11:55 11:55-12:10 | Sanofi Industry Sponsored Symposium | HALL A Unravelling CIDP: Exploring the Role of Complement Welcome and Introduction: Understanding heterogeneity, disease burden, and disability in CIDP Prof. Dr. Helmar Christoph Lehmann, Germany Demyelination and Axonal Damage in CIDP: Where Complement Fits In Prof. Dr. Helmar Christoph Lehmann, Germany Opportunities to Target the Pathobiology of CIDP Yuri Falzone, Italy Live Q&A Discussion Panel | |
| 12:20-13:10 12:20-12:30 12:30-12:40 12:40-12:50 12:50-13:00 13:00-13:10 | Meet the Expert Session sponsored by Medison | MTE HALL Advancing Care in Myasthenia Gravis: Clinical Insights and Real-World Impact Welcome & Opening, Latest gMG Guidelines Chair & Moderator: Assoc. Prof. Viktorija Kenina, Latvia Latest Clinical Evidence: Vyvgart and Emerging Data in Myasthenia Gravis The Importance of using MG-ADL and its Application in Clinical Practice Speaker: Assoc. Prof. Viktorija Kenina, Latvia Transforming Lives with Vyvgart: Real-World Experience and Patient Success Stories from Romania Speaker: Assoc. Prof. Dr Raluca Tudor, MD – Head of Neurology II Department, Victor Babes Medicine University Timisoara, Romania Real‑World Experience with Vyvgart in Polish gMG Patients: Insights from Clinical Practice Speaker: Prof. Konrad Rejdak, Poland Discussion Q&A |  |
| SATURDAY, MARCH 28, 2026 | ||
| 11:40-12:40 11:40-11:45 11:45-12:00 12:00-12:15 12:15-12:30 12:30-12:40 | argenx/Medison Industry Sponsored Symposium | HALL A FcRn blockade in CIDP & gMG: Clinical and real world evidence guiding treatment goals and practice Brief introduction, objectives, and disclosures Moderator: Prof. Anna Kostera-Pruszczyk, Poland FcRn blockade: The science behind IgG modulation and the argenx Immunology Innovation Program Speaker: Dr. Peter Ulrichts, Belgium (Chief Scientific Officer argenx) Efgartigimod in gMG: Clinical evidence and real-world data shaping care Speaker: Prof. Anna Kostera-Pruszczyk, Poland Efgartigimod in CIDP: Insights From the ADHERE Program and Emerging Real World Evidence Speaker: Dr. Amir Dori, Israel Panel Discussion and Audience Q&A and Closing Remarks Moderator: Prof. Anna Kostera-Pruszczyk, Poland |  |
